(Reuters) - New York City's comptroller on Thursday criticized what he said are "exorbitant" price increases for Mylan NV's allergy auto-injector EpiPen and said weak board oversight of management decisions had undermined the company's reputation and its stock price.
Read more
No comments:
Post a Comment